NSE · INDSWFTLAB
Ind-Swift Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹235 Cr with net profit ₹31 Cr — a 13.21% net margin, versus 13.13% the period before.
Shareholding
As of 2026-09-30
- Promoter42.93%
- Public46.09%
- FII10.78%
- DII0.2%
42,667 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 4.9× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #44 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Ind-Swift Laboratories Ltd.(this company) | ₹3,028 Cr | 33 | 2.05 | 6.22% | 11.1% |
AI analysis
AI-generated · google/gemini-2.5-flashInd-Swift Laboratories Ltd. is listed with a market capitalization of Rs 2035 Cr. The company reported revenue of Rs 643.09 Cr and a profit margin of 6.61%. The debt-to-equity ratio stands at 0.02. The promoter holding is 42.93%, while public shareholding is 46.2%.
Positives
- +The company has a low debt-to-equity ratio of 0.02.
- +The Return on Equity (ROE) is high at 357.5%.
- +No promoter shares are reported as pledged.
Negatives
- −Revenue declined by -67.1% in the last fiscal year.
- −The company has a low Return on Capital Employed (ROCE) of 4.3628%.
- −Ind-Swift Laboratories Ltd. is under ST-ASM surveillance, indicating increased regulatory monitoring.
- −The promoter holding decreased from 41.9958% in Jan 2020 to 42.93% in Jun 2026.
- −Quarterly net profit was negative at -5.49 Cr in Dec 2024.
Financial Performance
The company's revenue last fiscal year was Rs 643.09 Cr. Revenue growth experienced a decline of -67.1%. The net profit margin for the period was 6.61%. The last reported EPS is Rs 5.69.
Profitability & Returns
Ind-Swift Laboratories Ltd. recorded a Return on Equity (ROE) of 357.5% and a Return on Capital Employed (ROCE) of 4.3628%. The price-to-earnings (PE) ratio for the company is 129.28 based on the latest EPS of Rs 5.69.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.02, indicating minimal reliance on borrowed capital. Book value per share is Rs 159.17. No dividend yield was reported.
Ownership & Pledges
Promoter shareholding is 42.93%. There are no reported promoter pledges as of the latest data.
Regulatory & Surveillance
Ind-Swift Laboratories Ltd. is currently under ST-ASM surveillance, with multiple measures reported. This indicates increased monitoring by regulatory bodies due to specific criteria met by the company's stock.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Ind-Swift Laboratories Ltd.share price & fundamentals